首頁 > 市場調查報告書 > 製藥

疫苗基因治療學和RNAi

自擴增RNA合成市場規模、佔有率和成長分析：按產品類型、技術、應用領域、給藥途徑、最終用戶和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

1964350

自擴增RNA合成市場規模、佔有率和成長分析：按產品類型、技術、應用領域、給藥途徑、最終用戶和地區分類－2026-2033年產業預測

Self-amplifying RNA Synthesis Market Size, Share, and Growth Analysis, By Product Type (Premade saRNA, Enzymes & Reagents), By Technology, By Application Area, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年02月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024年全球自擴增RNA合成市值為1.0643億美元，預計將從2025年的1.2686億美元成長到2033年的5.1707億美元。預測期（2026-2033年）的複合年成長率預計為19.2%。

全球自擴增RNA合成市場專注於創新生產技術，這些技術能夠使RNA分子在細胞內複製，從而顯著降低疫苗和治療藥物的劑量需求和成本。這一轉變正吸引生物技術公司和契約製造日益成長的興趣，因為它有助於在突發公共衛生事件中提高藥物取得和快速反應。在體外轉錄、奈米顆粒遞送和監管理解等方面的進步推動下，市場發展已從早期學術研究階段發展到早期臨床試驗階段。生產的擴充性至關重要。自擴增技術減少了所需的RNA量，即使是小規模批量生產也能滿足廣泛的市場需求。人工智慧技術透過自動化設計和製造流程、序列最佳化、結果預測和參數最佳化來提高效率，縮短開發週期並最大限度地減少廢棄物。這推動了產能和市場機會的成長。

全球自擴增RNA合成市場促進因素

近年來，脂質奈米顆粒製劑、標靶遞送配體和生產技術的進步顯著提高了自擴增RNA構建體的穩定性、細胞內吸收率和組織靶向性。這些創新使得轉化效率更高，治療效果更佳，且所需劑量更小。這些改進的遞送技術降低了生物屏障，提高了全身性和局部給藥的實用性，促進了產業界和學術研究人員之間的投資與合作。這種合作環境反過來又加速了新產品候選藥物的開發平臺，增強了市場信心，並推動了自擴增RNA合成解決方案在治療藥物研發中的廣泛應用。

全球自擴增RNA合成市場面臨的限制因素

自擴增RNA的合成流程複雜，涉及精細的生產、純化和製劑製程。這些要求需要先進的技術專長和專業設施，這對旨在進入市場的中小型企業來說是一個挑戰。生產的複雜性會導致研發週期延長、產量受限以及潛在的供應鏈瓶頸。此外，客製化的工藝驗證和熟練人員的配備也構成了營運障礙，並增加了固定成本。因此，這些因素阻礙了新候選物質的快速生產，並限制了整體市場成長。

自擴增RNA合成市場的全球趨勢

全球自擴增RNA合成市場正經歷一場變革，其驅動力主要來自於遞送平台的創新。隨著研發人員不斷提升自擴增RNA療法的穩定性、細胞內攝取和標靶表達能力，市場對先進的脂質體配方、載體設計和偶聯技術給予了高度關注，旨在增強組織特異性和給藥便利性。這些突破將擴大市場的治療應用範圍，使其超越疫苗範疇，透過持續表達和低頻給藥，應用於慢性病和罕見疾病的治療。此外，策略性投資和研究合作正在加速平台成熟，打造出各具特色的產品，這些產品在遞送性能和以患者為中心的給藥方案方面具有競爭優勢。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場公司採取的策略
近期市場趨勢
企業市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 2023-2025年營收年比比較

主要企業簡介

Moderna, Inc.
BioNTech SE
CureVac AG
Ginkgo Bioworks, Inc.
Zymeworks Inc.
Imperial College London（Department of Chemical Engineering）
Aarhus University
GreenLight Biosciences, Inc.
Transgene SA
eTheRNA Immunotherapies
Medigen Vaccine Biologics Corp.
Vaxart, Inc.
Synlogic, Inc.
Tiba Biotech
Aibio Pharma
Acuitas Therapeutics
RiboBio Co., Ltd.
Codiak BioSciences, Inc.
iBio, Inc.
Egenesis, Inc.

結論與建議

簡介目錄

Product Code: SQMIG35H2418

Global Self-Amplifying Rna Synthesis Market size was valued at USD 106.43 Million in 2024 and is poised to grow from USD 126.86 Million in 2025 to USD 517.07 Million by 2033, growing at a CAGR of 19.2% during the forecast period (2026-2033).

The global self-amplifying RNA synthesis market focuses on innovative production technologies allowing RNA molecules to replicate within cells, significantly lowering vaccine and therapeutic dosage requirements and costs. This shift facilitates greater accessibility and quicker responses during health emergencies, drawing increased interest from biotech companies and contract manufacturers. Market development has evolved from early academic investigations to initial clinical trials, boosted by advancements in in vitro transcription, nanoparticle delivery, and regulatory familiarity. Manufacturing scalability is crucial, as self-amplification reduces the necessary RNA mass, enabling smaller production runs while meeting extensive demands. AI technology enhances efficiency by automating design and manufacturing processes, optimizing sequences, predicting outcomes, and refining parameters, thereby shortening development timelines and minimizing waste, thus propelling growth in both production capabilities and market opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Self-Amplifying Rna Synthesis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Self-Amplifying Rna Synthesis Market Segments Analysis

Global self-amplifying rna synthesis market is segmented by product type, technology, application area, route of administration, end user and region. Based on product type, the market is segmented into Premade saRNA, Enzymes & Reagents, Kits & Consumables and Other Related Products. Based on technology, the market is segmented into In Vitro Synthesis and In Vivo Synthesis. Based on application area, the market is segmented into Therapeutics Development and Biomedical Research. Based on route of administration, the market is segmented into Intramuscular (IM), Subcutaneous (SC), Intradermal (ID) and Intravenous (IV). Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations (CDMOs), Academic & Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Self-Amplifying Rna Synthesis Market

Recent advancements in lipid nanoparticle formulations, targeted delivery ligands, and manufacturing techniques have significantly enhanced the stability, cellular absorption, and tissue targeting of self-amplifying RNA constructs. These innovations lead to more effective translation and therapeutic effects while minimizing dosage requirements. By mitigating biological barriers, these delivery enhancements improve the viability of both systemic and localized applications, fostering increased investment and collaboration between industry and academic researchers. Consequently, this collaborative environment accelerates the progression of new product candidates through the development pipeline, bolstering market confidence and promoting wider adoption of self-amplifying RNA synthesis solutions among therapeutic developers.

Restraints in the Global Self-Amplifying Rna Synthesis Market

The synthesis of self-amplifying RNA is characterized by complex workflows that involve meticulous production, purification, and formulation processes. These requirements demand significant technical expertise and specialized facilities, which can create challenges for smaller companies aiming to enter the market. The intricate nature of manufacturing can extend development timelines and restrict throughput, leading to potential supply chain bottlenecks. Additionally, the necessity for customized process validation and the recruitment of skilled personnel contribute to higher operational barriers and fixed costs. Consequently, these factors hinder the rapid production of new candidates, ultimately restraining the overall growth of the market.

Market Trends of the Global Self-Amplifying Rna Synthesis Market

The Global Self-Amplifying RNA Synthesis market is experiencing a transformative shift driven by innovations in delivery platforms. As developers enhance stability, cellular uptake, and targeted expression of self-amplifying RNA therapeutics, there is a clear focus on advanced lipid formulations, vector engineering, and conjugation methods to improve tissue specificity and dosing convenience. These breakthroughs expand the market's therapeutic reach beyond vaccines, facilitating applications in chronic and rare diseases through sustained expression with lower administration frequency. Furthermore, strategic investments and research collaborations are fostering platform maturation, resulting in distinct product profiles that offer competitive advantages centered on delivery performance and patient-centric administration options.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape
Technology Analysis
Value Chain Analysis

Global Self-amplifying RNA Synthesis Market Size by Product Type & CAGR (2026-2033)

Market Overview
Premade saRNA
Enzymes & Reagents
Kits & Consumables
Other Related Products

Global Self-amplifying RNA Synthesis Market Size by Technology & CAGR (2026-2033)

Market Overview
In Vitro Synthesis
In Vivo Synthesis

Global Self-amplifying RNA Synthesis Market Size by Application Area & CAGR (2026-2033)

Market Overview
Therapeutics Development
- Infectious Diseases
- Oncology
- Gene & Protein Therapy
- Other Therapeutic Applications
Biomedical Research

Global Self-amplifying RNA Synthesis Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intramuscular (IM)
Subcutaneous (SC)
Intradermal (ID)
Intravenous (IV)

Global Self-amplifying RNA Synthesis Market Size by End User & CAGR (2026-2033)

Market Overview
Pharmaceutical & Biotechnology Companies
Contract Development & Manufacturing Organizations (CDMOs)
Academic & Research Institutes
Others

Global Self-amplifying RNA Synthesis Market Size & CAGR (2026-2033)

North America (Product Type, Technology, Application Area, Route of Administration, End User)
- US
- Canada
Europe (Product Type, Technology, Application Area, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product Type, Technology, Application Area, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product Type, Technology, Application Area, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Product Type, Technology, Application Area, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Moderna, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CureVac AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ginkgo Bioworks, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Imperial College London (Department of Chemical Engineering)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aarhus University
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GreenLight Biosciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Transgene SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
eTheRNA Immunotherapies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medigen Vaccine Biologics Corp.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxart, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Synlogic, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tiba Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aibio Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acuitas Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RiboBio Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Codiak BioSciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
iBio, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Egenesis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments